Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta‐Analysis
Journal of Viral Hepatitis · 2025
DOI: 10.1111/jvh.70078 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Jing Xiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Sofosbuvir, Heterocyclic Compounds, 4 or More Rings, Antiviral Agents, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
To assess the efficacy and safety of the Velpatasvir (VEL)/Sofosbuvir (SOF) with or without Ribavirin (RBV) in treating patients with decompensated hepatitis C cirrhosis. We searched multiple databases for studies published from October 2010 to September 2024. Outcomes of interest were sustained viral response at 12 weeks (SVR12) and the safety of VEL/SOF with and without RBV regimens in patients with decompensated hepatitis C virus (HCV) cirrhosis. All statistical analyses were performed using R Statistics (4.4.1). We included 13 studies that enrolled 872 adult patients with decompensated cirrhosis due to HCV. The addition of RBV to the VEL/SOF regimen neither significantly improved SVR12 after the last dose of treatment [95.0% (366/391, 95% CI: 89.0–99.0) vs. 94.0% (442/481, 95% CI: 90.0–97.0); p = 0.92] nor decreased virologic relapse [1.0% (2/158, 95% CI: 0.0–8.0) vs. 6.0% (12/197, 95% CI: 3.0–10.0); p = 0.15]. VEL/SOF plus RBV therapy had a significantly higher rate of adverse events [92.0% (261/287, 95% CI: 88.0–95.0) vs. 47.0% (167/348, 95% CI: 24.0–71.0); p < 0.01] and death [7.0% (20/287, 95% CI: 2.0–16.0) vs. 2.0% (8/366, 95% CI: 1.0–4.0); p = 0.05]. However, for patients with genotype 3, adding RBV to the VEL/SOF regimen significantly improved SVR12 [87.0% (26/30, 95% CI: 71.0–98.0) vs. 45% (7/15, 95% CI: 13.0–79.0); p < 0.01] and decreased virologic relapse [0.0% (0/10, 95% CI: 0.0–31.0) vs. 100% (1/1, 95% CI: 2.0–100.0); p = 0.02]. VEL/SOF based therapy is a safe and effective treatment for patients with decompensated cirrhosis due to HCV. The addition of RBV to VEL/SOF may increase toxicity without achieving improved efficacy overall. However, the addition of RBV significantly increased the SVR12 rate and reduced the virologic relapse in genotype 3 patients. Trial Registration: PROSPERO database: CRD42023491852
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
ORCID-Profile: Yunjian Sheng
Zitieren
APA
Xiao, J., Zhang, X., Mao, X., Lai, S., Li, S., & Sheng, Y. (2025). Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta‐Analysis. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70078
Vancouver
Xiao J, Zhang X, Mao X, Lai S, Li S, Sheng Y. Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta‐Analysis. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70078
BibTeX
@article{Xiao2025,
author = {Xiao, Jing and Zhang, Xinnian and Mao, Xiaozhou and Lai, Shunhao and Li, Shuangli and Sheng, Yunjian},
title = {Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta‐Analysis},
journal = {Journal of Viral Hepatitis},
year = {2025},
doi = {10.1111/jvh.70078}
}
EUVIMED